Vicarious Surgical (NYSE:RBOT) announced today that the NYSE has commenced the process of delisting its stock.
The Waltham, Massachusetts–based surgical robot developer received a notice from the stock exchange yesterday, March 3, 2026. As a result of the NYSE action, the company’s stock was suspended after market close.
Shares of RBOT are currently trading at $1.92 apiece ahead of the opening of the NYSE market today.
Vicarious said that the NYSE determined that its stock fell below the continued listing standard. It requires companies to maintain an average global market capitalization over a consecutive 30-day trading period of at least $15 million.
The company must make an appeal within 10 business days from receipt of the notice. It said it currently has a potential appeal under evaluation. Meanwhile, the company received approval to have its stock quoted on the OTCID market tier operated by the OTC Markets Group. It expects common stock to begin quotation on that market at the open of business today, March 4, 2026. The company intends to continue trading under the “RBOT” ticker.
This isn’t the first time the company has faced delisting, having fallen below NYSE standards in 2023. It then conducted a reverse stock split midway through 2024.
The latest on Vicarious Surgical’s efforts
Potential delisting comes at an interesting time for Vicarious, which has been advancing a surgical robotic platform for some time, but has hit various snags along the way.
Vicarious designed its robot to increase the efficiency of surgical procedures. The company previously set its sights on first-in-human trials midway through 2025, but delayed the robot’s timeline back in November 2023. Then, in March 2024, the company outlined plans to have its “V1.0” system ready for an FDA submission by early to mid-fiscal 2026.
In late 2024, the company said it planned for a year-end cadaver lab for V1.0, followed by efforts toward verification, validation, and optimization of the system ahead of formal clinical testing. In May 2025, Vicarious announced a new hospital collaboration, moving closer to bringing its surgical robot technology to patients. But, in August, the company said it would hold off on clinical trial initiation to further develop its robot. At that time, the company earmarked the end of 2026 for its design freeze.
At the start of this year, the company successfully completed an in-vivo porcine lab for the robot. It said the lab reinforces its progress toward a system design freeze earmarked for the end of 2026.
